Latest Insider Transactions at Sera Prognostics, Inc. (SERA)
This section provides a real-time view of insider transactions for Sera Prognostics, Inc. (SERA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SERA PROGNOSTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SERA PROGNOSTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 29
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.71%
|
$1,000
$1.72 P/Share
|
Jun 29
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.68%
|
$0
$0.73 P/Share
|
Jun 28
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-4.53%
|
$2,725
$1.89 P/Share
|
Jun 21
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-4.34%
|
$2,725
$1.31 P/Share
|
Jun 14
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-4.15%
|
$2,725
$1.21 P/Share
|
Jun 14
2022
|
Benjamin Jackson General Counsel |
BUY
Open market or private purchase
|
Direct |
8,000
+50.0%
|
$8,000
$1.2 P/Share
|
Jun 07
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.99%
|
$2,725
$1.3 P/Share
|
Jun 01
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.44%
|
$1,000
$1.36 P/Share
|
Jun 01
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.42%
|
$0
$0.73 P/Share
|
May 31
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.84%
|
$2,725
$1.45 P/Share
|
May 24
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.69%
|
$2,725
$1.54 P/Share
|
May 17
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.56%
|
$2,725
$1.55 P/Share
|
May 10
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.44%
|
$2,725
$1.97 P/Share
|
May 04
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.25%
|
$2,000
$2.17 P/Share
|
May 04
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.23%
|
$0
$0.73 P/Share
|
May 03
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.33%
|
$5,450
$2.17 P/Share
|
Apr 26
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.22%
|
$5,450
$2.17 P/Share
|
Apr 19
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.12%
|
$5,450
$2.08 P/Share
|
Apr 12
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.02%
|
$5,450
$2.66 P/Share
|
Apr 06
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.1%
|
$3,000
$3.02 P/Share
|
Apr 06
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.09%
|
$0
$0.73 P/Share
|
Apr 05
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-2.94%
|
$8,175
$3.35 P/Share
|
Mar 29
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-2.85%
|
$8,175
$3.73 P/Share
|
Mar 22
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-2.77%
|
$8,175
$3.68 P/Share
|
Mar 14
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-2.7%
|
$8,175
$3.94 P/Share
|
Mar 11
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,998
+42.93%
|
$0
$0.73 P/Share
|
Dec 06
2021
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,012
+50.0%
|
$0
$0.73 P/Share
|
Jul 19
2021
|
Blue Ox Healthcare Partners, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,795,150
+50.0%
|
-
|
Jul 19
2021
|
Joshua Phillips |
BUY
Conversion of derivative security
|
Indirect |
927,562
+12.86%
|
-
|
Jul 19
2021
|
Ryan Trimble Director |
BUY
Conversion of derivative security
|
Indirect |
63,005
+13.72%
|
-
|
Jul 19
2021
|
Gregory C Critchfield Director |
BUY
Conversion of derivative security
|
Direct |
84,973
+2.15%
|
-
|
Jul 19
2021
|
Jay M Moyes Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
2,830
+30.85%
|
-
|